This position may be based in either our Florham Park, NJ or Lake County, IL office.

The Director, Neuroscience PCS – NeuroImmunology (NI Director) is responsible for building a foundational neuroimmunology portfolio within AbbVie that will complement our existing leading neuroscience and immunology businesses. The NI Director will develop the pipeline commercial strategy for our neuroimmunology assets, including our internal portfolio of products as well as complementary external programs which they will help evaluate in partnership with our business development colleagues. Relevant diseases within this strategy include multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and several others. The NI Director will shape the commercial plans for each of our prioritized assets and will be the champion of this strategy across stages of governance as these assets are advanced through the development pipeline.

Primary responsibilities of this role include: (1) developing disease area strategies for our prioritized neuroimmunology diseases in partnership with the Corporate Business & Strategy Office, (2) developing early brand plans and integrated value propositions for leading assets, (3) building forecasts for each asset in partnership with the pipeline finance group to support the long-range plan, and (4) partnering closely with clinical development, asset management, and on-market commercial teams to ensure strategies are supported broadly across stakeholders.

Reporting to the Neurodegeneration PCS lead, the NI Director will also lead the cross-functional Brand Strategy Team (BST) collaborating with Market Access, Medical Affairs, R&D, HEOR, Finance, and Market Research (among others) to drive both commercial planning and forecasting deliverables.

Key Job Responsibilities:

• Lead early commercialization functions including early brand plan, integrated value proposition, forecasting and value metrics, lifecycle planning, and global market assessments for each asset in the neuroimmunology pipeline portfolio
• Represent each asset in the AST, IEST, VAT, LRST, PPDST and lead the BST in development of early commercialization deliverables for each asset
• Design and shape clinical and medical evidence generation plans in partnership with R&D and Medical Affairs
• Participate in cross-functional governance meetings, including go to Phase 2/3 milestones as well as late-stage development governance such as CFG
• Partner with PCS Insights and APEX teams to develop and validate value propositions through HCP and patient engagement and research
• Lead discussions with key opinion leaders to garner insights in the development and commercialization of assets through one-on-one interactions as well as ad boards or roundtable discussions
• Develop compelling presentations to convey strategies to broad sets of stakeholder audiences, including senior executives, cross-functional leadership teams, and cross-functional partners for understanding and support of development plans
• Work with Global Affiliates by leading Touch Points to gain insights for key launch markets for each asset, incorporating these into the global commercialization recommendation
• Work alongside Search and Eval, BD and Commercial Assessment colleagues in the evaluation of complementary opportunity evaluations for the neuroimmunology portfolio
• Evaluate opportunities for complementary or expansive indications for lead assets or competitive compounds in development, including positioning and co-positioning evaluations